Drugs / RBV
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00959699 Comparator | Nov 2009 → May 2012 | HIV infectious disease, hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00959699 ↗ |
| Route | Oral | “Ribavirin (600-1400 mg/day, orally, divided into two daily doses)” NCT00959699 ↗ |